Journal article
Determining research priorities for clinician-initiated trials in infectious diseases
DL Paterson
Medical Journal of Australia | WILEY | Published : 2013
DOI: 10.5694/mja12.11703
Abstract
Objectives: To determine research priorities of infectious diseases physicians for clinician-initiated randomised controlled trials (RCTs). Design, setting and participants: Online survey of infectious diseases physicians in Australia and New Zealand. Main outcome measures: Research priorities for, and perceived barriers to, clinician-initiated RCTs. Results: 122/550 infectious diseases physicians (22%) responded to the survey. The five highest ranked proposals for clinician-initiated RCTs were in the areas of prosthetic joint infections, septic arthritis and osteomyelitis of native joints, Staphylococcus aureus bloodstream infections, diabetic foot infections and the treatment of serious mu..
View full abstractGrants
Funding Acknowledgements
Tania Sorrell has received untied research funds from Gilead Sciences, Merck, Sharp & Dohme and Pfizer Pharmaceuticals and has been a member of their respective antifungal advisory boards Sharon Chen has served on the antifungal advisory boards of Pfizer Australia, Merck, Sharp & Dohme and Gilead Sciences and has received educational grants from Pfizer Australia, Merck, Sharp & Dohme and Gilead Sciences. Narin Bak has received financial sponsorship for travel-related educational meetings from Merck, Sharp & Dohme, Gilead Sciences and Pfizer and honoraria for educational lectures from Merck, Sharp & Dohme. He has undertaken clinical trials with antivirals and other antibiotics for many other pharmaceutical companies. David Paterson has served as a consultant or on advisory boards for AstraZeneca, Merck, Sharp & Dohme, Pfizer, Cubist, Leo Pharmaceuticals, Novartis, Johnson and Johnson, Bayer, Trius and Achaogen, and has received honoraria for educational lectures from AstraZeneca and research funds from Sanofi Aventis.